JD Health (06618.HK) jumped nearly 4% in Hong Kong trading, rising 3.31% to HK$45.2 by press time with turnover reaching HK$385 million. The rally follows Innovent Bio's announcement of a strategic cooperation agreement with JD Health. Both companies will deepen collaboration across pharmaceutical supply chains, omni-channel sales, and digital marketing, leveraging their respective strengths to deliver diverse, high-quality medicines and health services to consumers.

JD Health CEO Jin Enlin emphasized the company's commitment to improving medicine accessibility through technological innovation in healthcare, aiming to make medical resources more accessible and intelligent. He expressed optimism about exploring further partnerships in oncology and chronic disease management.

Concurrently, UBS projected JD Health's Q2 revenue growth at 17-19% year-over-year, implying first-half growth exceeding 20%—above market expectations of 18.6%. The bank cited expanding product margins and robust advertising revenue as key drivers for sustained gross margin improvement. Nomura analysts echoed the sentiment, anticipating better-than-expected H1 revenue and profits.